規制動向

FDA、EMA、TGA および世界の規制動向

#Lidocaine ×

2026年9月24日•1分で読めます

FDA Approves ANDA217117 for LIDOCAINE Topical Ointment

The FDA has approved Aurobindo Pharma's LIDOCAINE 5% topical ointment (ANDA217117) for prescription use, with a standard review completed on June 18, 2024.

2026年9月23日•1分で読めます

FDA Approves Lidocaine Hydrochloride Injection (NDA 017584)

The FDA has approved preservative‑free lidocaine hydrochloride injectable products (2% and 4%) under NDA 017584, manufactured by Fresenius Kabi USA.

2026年9月23日•1分で読めます

FDA Approves Multiple Supplemental Applications for LIDOPEN (NDA 017549)

The FDA has granted approval for several supplemental submissions related to LIDOPEN, an injectable lidocaine product now discontinued.

2026年9月9日•1分で読めます

FDA Approves Multiple Submissions for Lidocaine Hydrochloride Injection (Discontinued Product)

The FDA has approved several labeling and manufacturing submissions for the discontinued injectable lidocaine hydrochloride (2%) product.

2026年8月31日•1分で読めます

FDA Approves ANDA083389 for Lidocaine Hydrochloride with Epinephrine Injection (Discontinued)

The FDA approved ANDA083389 for a lidocaine hydrochloride 1% injection containing 0.01 mg/mL epinephrine, submitted by Dell Labs; the product is listed as discontinued.

2026年8月30日•1分で読めます

FDA Approves Manufacturing Submissions for XYLOCAINE Ointment (NDA 008048)

The FDA record for NDA 008048 shows XYLOCAINE ointment, a discontinued 5% lidocaine topical, received multiple approved manufacturing and labeling submissions from 1984 to 1996.

2026年8月24日•1分で読めます

FDA Approves LIDOCAINE AND PRILOCAINE Topical Cream (ANDA076320)

The FDA approved ANDA076320 for a prescription topical cream containing 2.5% lidocaine and 2.5% prilocaine, manufactured by Encube Ethicals.